AZD4818

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Chronic Obstructive Pulmonary Disease (COPD)Healthy

Phase 1

Safety, Tolerability and Pharmacokinetics of Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers

CompletedNCT00687232

AstraZenecaHealthy

Start: 2008-01-31End: 2008-05-31Target: 30Updated: 2010-12-01

Phase 2

Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00629239

AstraZenecaChronic Obstructive Pulmonary Disease (COPD)

Start: 2008-01-31End: 2008-08-31Updated: 2010-12-06

Related Papers

Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients.

2010-05-1333 citations